0001209191-23-053487.txt : 20231024
0001209191-23-053487.hdr.sgml : 20231024
20231024172248
ACCESSION NUMBER: 0001209191-23-053487
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231023
FILED AS OF DATE: 20231024
DATE AS OF CHANGE: 20231024
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kassberg Thomas Richard
CENTRAL INDEX KEY: 0001303811
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36276
FILM NUMBER: 231343461
MAIL ADDRESS:
STREET 1: C/O ULTRAGENYX PHARMACEUTICAL INC.
STREET 2: 60 LEVERONI COURT
CITY: NOVATO
STATE: CA
ZIP: 94949
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Ultragenyx Pharmaceutical Inc.
CENTRAL INDEX KEY: 0001515673
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 272546083
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 60 LEVERONI COURT
CITY: NOVATO
STATE: CA
ZIP: 94949
BUSINESS PHONE: 415-483-8800
MAIL ADDRESS:
STREET 1: 60 LEVERONI COURT
CITY: NOVATO
STATE: CA
ZIP: 94949
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-10-23
0
0001515673
Ultragenyx Pharmaceutical Inc.
RARE
0001303811
Kassberg Thomas Richard
C/O ULTRAGENYX PHARMACEUTICAL INC.
60 LEVERONI COURT
NOVATO
CA
94949
0
1
0
0
CBO & EVP
1
Common Stock
2023-10-23
4
M
0
39878
6.86
A
286738
D
Common Stock
2023-10-23
4
S
0
39878
32.78
D
246860
D
Stock Option (Right to Buy)
6.86
2023-10-23
4
M
0
39878
0.00
D
2023-10-31
Common Stock
39878
0
D
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.09 to $33.18 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
The option vested with respect to 1/4th of the shares on the first anniversary of the grant date of the option and 1/48th of the shares thereafter such that the option fully vested on the fourth anniversary of the grant date.
/s/ Karah Parschauer, attorney-in-fact
2023-10-24